ANTI-CD19 ANTIBODY HAVING ADCC FUNCTION WITH IMPROVED GLYCOSYLATION PROFILE
    1.
    发明公开
    ANTI-CD19 ANTIBODY HAVING ADCC FUNCTION WITH IMPROVED GLYCOSYLATION PROFILE 审中-公开
    抗体CD19抗原激素MIT ADCC-FUNKTION UND VERBESSERTEM GLYKOSYLIERUNGSPROFIL

    公开(公告)号:EP2596024A1

    公开(公告)日:2013-05-29

    申请号:EP11736051.1

    申请日:2011-07-18

    IPC分类号: C07K16/28 A61K47/48

    摘要: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.

    摘要翻译: 本发明涉及具有相对于野生型Fc区具有特定氨基酸修饰的变体Fc区的抗CD19抗体,其赋予一种或几种有用的效应子功能。 本发明特别涉及包含这种变体Fc区的嵌合,人源化或全人抗CD19抗体。 其有利地涉及具有有趣和有价值的糖基化谱,特别是低岩藻糖水平和/或高寡甘露糖水平和/或唾液酸,高ADCC功能的存在和没有CDC的抗体。 本发明还涉及这些抗体在治疗,预防或治疗诸如癌症,特别是B细胞恶性肿瘤和自身免疫疾病的疾病或病症中的用途。